Can a 10-day antiviral course protect kidney transplant patients from severe COVID?
Disease control
Recruiting now
This study tests whether a 10-day course of the antiviral drug remdesivir can prevent severe COVID-19 in kidney transplant recipients who have mild or no symptoms. About 15 adults with end-stage kidney disease who test positive for SARS-CoV-2 will receive remdesivir starting just…
Phase: PHASE2 • Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia • Aim: Disease control
Last updated May 14, 2026 12:05 UTC